AC IMMUNE SA SF-02 (IMR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AC IMMUNE SA SF-02 (IMR) has a cash flow conversion efficiency ratio of -0.368x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-16.51 Million ≈ $-19.30 Million USD) by net assets (€44.88 Million ≈ $52.47 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see AC IMMUNE SA SF-02 stock valuation for the company's overall valuation and market capitalisation.
AC IMMUNE SA SF-02 - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how AC IMMUNE SA SF-02's cash flow conversion efficiency has evolved over time, based on yearly financial data.
AC IMMUNE SA SF-02 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AC IMMUNE SA SF-02 ranked by their cash flow conversion efficiency. Explore AC IMMUNE SA SF-02 (IMR) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Stellus Capital Investment
NYSE:SCM
|
154752.995x |
|
Hocheng Corp
TW:1810
|
-0.001x |
|
Venus Remedies Limited
NSE:VENUSREM
|
0.136x |
|
Ard Grup Bilisim Teknolojileri AS
IS:ARDYZ
|
0.044x |
|
Cint Group AB
ST:CINT
|
0.036x |
|
Penns Woods Bancorp Inc
NASDAQ:PWOD
|
0.000x |
|
Empire Energy Group Ltd
AU:EEG
|
0.012x |
|
Samsung C and T 1P Pref
KO:02826K
|
0.026x |
Annual Cash Flow Conversion Efficiency for AC IMMUNE SA SF-02 (2021–2025)
The table below shows the annual cash flow conversion efficiency of AC IMMUNE SA SF-02 from 2021 to 2025. View IMR stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €44.88 Million ≈ $52.47 Million |
€-69.26 Million ≈ $-80.97 Million |
-1.543x | -363.13% |
| 2024-12-31 | €112.27 Million ≈ $131.26 Million |
€65.84 Million ≈ $76.98 Million |
0.586x | +255.96% |
| 2023-12-31 | €160.64 Million ≈ $187.81 Million |
€-60.41 Million ≈ $-70.62 Million |
-0.376x | +13.62% |
| 2022-12-31 | €168.99 Million ≈ $197.57 Million |
€-73.57 Million ≈ $-86.01 Million |
-0.435x | -53.74% |
| 2021-12-31 | €231.98 Million ≈ $271.21 Million |
€-65.69 Million ≈ $-76.80 Million |
-0.283x | -- |
About AC IMMUNE SA SF-02
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins … Read more